-
公开(公告)号：US20210186886A1
公开(公告)日：2021-06-24
申请号：US17080355
申请日：2020-10-26
Inventor： Arturo J. Vegas , Minglin Ma , Kaitlin M. Bratlie , Daniel G. Anderson , Robert S. Langer
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.
-
公开(公告)号：US10898443B2
公开(公告)日：2021-01-26
申请号：US16108465
申请日：2018-08-22
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC: A61K35/39 , A61K9/00 , A61K9/50 , A61L29/08 , A61L31/10 , C08B37/00 , C12N5/00 , C12N5/071 , A61L33/08
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
公开(公告)号：US10292936B2
公开(公告)日：2019-05-21
申请号：US15588481
申请日：2017-05-05
Inventor： Arturo J. Vegas , Minglin Ma , Kaitlin M Bratlie , Daniel G. Anderson , Robert S. Langer
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.
-
4.发明申请Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates 有权用于包封细胞和细胞聚集体的多层水凝胶胶囊公开(公告)号：US20140271843A1
公开(公告)日：2014-09-18
申请号：US13831250
申请日：2013-03-14
Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Arturo Jose Vegas , Joshua Charles Doloff
CPC classification number: A61K35/39 , A61K9/0024 , A61K9/5036 , A61K9/5078 , A61K9/5089 , A61K2035/126 , A61K2035/128 , B01J13/046
Abstract: Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
Abstract translation: 公开了包封直径大于1mm的哺乳动物细胞和任选的无细胞核的生物相容性水凝胶胶囊，其在植入受试者后具有减少的纤维化过度生长。 还公开了治疗受试者疾病的方法，其涉及向受试者施用治疗有效量的所公开的封闭细胞。
-
公开(公告)号：US11446239B2
公开(公告)日：2022-09-20
申请号：US17024148
申请日：2020-09-17
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup , Arturo Jose Vegas
Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
Patent Agency Ranking
公开(公告)号：US10729818B2
公开(公告)日：2020-08-04
申请号：US15588475
申请日：2017-05-05
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC: A61L29/08 , A61K47/36 , A61K9/48 , A61K35/39 , C08B37/00 , A61K9/00 , A61K9/50 , A61L31/10 , A61L33/08 , C07D487/04 , C12N5/00 , C12N5/071
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
公开(公告)号：US20190091139A1
公开(公告)日：2019-03-28
申请号：US16200334
申请日：2018-11-26
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup , Arturo Jose Vegas
Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US20180353643A1
公开(公告)日：2018-12-13
申请号：US15573926
申请日：2016-05-17
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Arturo Jose Vegas , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup
CPC classification number: A61L27/20 , A61F2/02 , A61F2230/0071 , A61F2240/001 , A61F2250/0068 , A61L27/3804 , A61L27/52 , A61L27/54 , A61L2300/64 , A61L2400/18 , A61M31/002 , A61M2205/04 , A61M2207/00
Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
9.发明授权Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates 有权用于包封细胞和细胞聚集体的多层水凝胶胶囊公开(公告)号：US09555007B2
公开(公告)日：2017-01-31
申请号：US13831250
申请日：2013-03-14
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Arturo Jose Vegas , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup
CPC classification number: A61K35/39 , A61K9/0024 , A61K9/5036 , A61K9/5078 , A61K9/5089 , A61K2035/126 , A61K2035/128 , B01J13/046
Abstract: Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
Abstract translation: 公开了包封直径大于1mm的哺乳动物细胞和任选的无细胞核的生物相容性水凝胶胶囊，其在植入受试者后具有减少的纤维化过度生长。 还公开了治疗受试者疾病的方法，其涉及向受试者施用治疗有效量的所公开的封闭细胞。
-
公开(公告)号：US11266606B2
公开(公告)日：2022-03-08
申请号：US16584170
申请日：2019-09-26
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC: A61K35/39 , A61K9/00 , A61K9/50 , A61L29/08 , A61L31/10 , C08B37/00 , C12N5/00 , C12N5/071 , A61L33/08
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.021 seconds)
